SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (162)5/23/2001 8:28:26 AM
From: aknahow   of 1022
 
Just suggesting that the cash angle no longer has the same importance it once did. True raising cash when stock price was much higher was a great move. This type of event should already be factored into the current price of the stock. Just don't see institutional investors being willing to take the risk of a biotech because it has a pile of money.

If the companies that raised funds still have big stash when it once again becomes difficult to raise capital, we will once again here about the advantages of cash. It may seem perverse but the best use of cash at present might be buying back the stock sold at higher prices.

Understand the feeling that cash is cash. Just pointing out that holding tons of cash in overnight, or very short term investments, does not provide the same comfort when rates are low.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News